Department of Nephrology, Shenzhen Second People's Hospital, Shenzhen, 518035, China; Health Science Center, The First Affiliated Hospital of Shenzhen University, Shenzhen, 518035, China.
Department of Nephrology, Shenzhen Hengsheng Hospital, Shenzhen, 518102, China.
Int Immunopharmacol. 2021 Nov;100:108124. doi: 10.1016/j.intimp.2021.108124. Epub 2021 Sep 30.
The microRNA (miRNA) expression of the tonsil tissues in patients with immunoglobulin A (IgA) nephropathy (IgAN) has not been reported in the literature.
In this study, the expression of nine miRNAs was measured in the tonsil tissues of patients with IgAN, including miRNA-21-5p, miRNA-29a-3p, miRNA-34a-5p, miRNA-146a-5p, miRNA-146b-5p, miRNA-148b-3p, miRNA-150-5p, miRNA-155-5p, and miRNA-181a-5p. Forty patients with proved primary IgA nephropathy were enrolled in our study, 20 IgAN patients with gross hematuria, which induced by tonsillitis (GH-IgAN group) and 20 IgAN patients without gross hematuria in the history (non-GH-IgAN group). Another 20 patients recruited as the control group (CT group) were chronic tonsillitis without kidney disease.
Compared to the CT group, the expression level of miRNA-150-5p in the tonsils was significantly upregulated in the GH-IgAN group, but not in the non-GH-IgAN group (P = 0.031 and P = 0.122, respectively). A correlation analysis was performed between the expression of miRNAs in the tonsils and the clinical data of IgAN patients. The results showed that in the GH-IgAN group, the miRNA-150 expression was positively correlated with systolic blood pressure (β = 2.36, 95% CI 1.11-3.61, P = 0.0016), diastolic blood pressure (β = 1.02, 95% CI 0.22-1.82, P = 0.0224), uric acid (β = 7.43, 95% CI 1.81-13.04, P = 0.0184), leukocyte count (β = 0.22, 95% CI 0.09-0.35, P = 0039), neutrophil count (β = 0.19, 95% CI 0.06-0.32, P = 0.0096), cholesterol (β = 0.09, 95% CI 0.02-0.16, P = 0.0207) and triglyceride level (β = 0.16, 95% CI 0.10-0.22, P < 0.000). Besides, it was negatively correlated with the estimated glomerular filtration rate (eGFR) (β = -2.06, 95% CI: -3.90 - -0.21, P = 0.0421) in the GH-IgAN group; however, no significant correlation was found in the non-GH-IgAN group.
The present findings suggest that miRNA-150-5p may be important in the pathogenesis of IgAN, especially in mucosal immunity against the disease.
文献中尚未报道扁桃体组织中免疫球蛋白 A（IgA）肾病（IgAN）患者的 microRNA（miRNA）表达情况。
在这项研究中，我们测量了 40 例经证实的原发性 IgA 肾病患者的扁桃体组织中 9 种 miRNA 的表达水平，包括 miRNA-21-5p、miRNA-29a-3p、miRNA-34a-5p、miRNA-146a-5p、miRNA-146b-5p、miRNA-148b-3p、miRNA-150-5p、miRNA-155-5p 和 miRNA-181a-5p。其中 20 例 IgAN 患者伴肉眼血尿（GH-IgAN 组），20 例 IgAN 患者无肉眼血尿史（非 GH-IgAN 组），均因扁桃体炎引起，另 20 例慢性扁桃体炎患者作为对照组（CT 组），无肾脏疾病。
与 CT 组相比，GH-IgAN 组扁桃体组织中 miRNA-150-5p 的表达水平明显升高，但在非 GH-IgAN 组中未升高（P=0.031 和 P=0.122）。对 IgAN 患者的临床数据进行了 miRNA 表达的相关性分析。结果表明，在 GH-IgAN 组中，miRNA-150 的表达与收缩压（β=2.36，95%CI 1.11-3.61，P=0.0016）、舒张压（β=1.02，95%CI 0.22-1.82，P=0.0224）、尿酸（β=7.43，95%CI 1.81-13.04，P=0.0184）、白细胞计数（β=0.22，95%CI 0.09-0.35，P=0.039）、中性粒细胞计数（β=0.19，95%CI 0.06-0.32，P=0.0096）、胆固醇（β=0.09，95%CI 0.02-0.16，P=0.0207）和甘油三酯水平（β=0.16，95%CI 0.10-0.22，P<0.000）呈正相关，与估计肾小球滤过率（eGFR）呈负相关（β=-2.06，95%CI：-3.90- -0.21，P=0.0421）；然而，在非 GH-IgAN 组中未发现明显相关性。
本研究结果表明，miRNA-150-5p 可能在 IgAN 的发病机制中起重要作用，尤其是在针对疾病的黏膜免疫中。
